Sunday, December 04, 2016 11:26:18 PM
Someone said: "NNVC warns the consistency problem is shared by other companies also failing. They all make batches that are unique from each other like snowflakes."
I asked where were the facts supporting this claim that NNVC claims that NNVC and other nanomedicine companies are all failing because they are unable to consistently produce their drugs? I allowed for the possibility that perhaps I was unaware of some facts, such as a filing or interview where NNVC claimed that they and all nanomedicine companies were unable to produce their drugs because of an alleged consistency problem from batch to batch.
I got no facts supporting this notion because there are none!
If you look at the 10-K, NNVC says "The nanoviricide technology has been designed from the ground up to enable consistent manufacture and control."
Other nanomedicine companies have solved the problem of manufacturing their drugs at a large scale and in a reproducible fashion. That's why $16B worth of nanomedicines were sold during 2015.
You and others claim that NNVC knows that they will never solve the manufacturing issue. I have asked repeatedly what evidence do you have to support this notion, other than conjecture? First, how do you know that NNVC knows this? Which NNVC employees stated this, and to whom?
The inability or delays in manufacturing their drugs is probably the biggest risk factor for NNVC, with possible toxicity the next biggest on my list.
You and others claim you know with certainty (and that NNVC knows this also and is illegally concealing this "fact") that they can never produce their drugs. Where are the facts supporting this notion, other than opinions about the delays?
If NNVC was having a problem with reproducibility, would they be able to send HerpeCide drug(s) to multiple labs and get the same results?
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • SONGD • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM